Literature DB >> 33118509

[miR-133b inhibits myocardial ischemia-reperfusion-induced cardiomyocyte apoptosis and accumulation of reactive oxygen species in rats by targeting YES1].

Xing Peng1, Ling Lin1, Xiangqun Zhou1, Daying Yang1, Yang Cao2, Taoyuan Yin1, Yuanyuan Liu3.   

Abstract

OBJECTIVE: To investigate the effect of miR-133b on cardiomyocyte apoptosis induced by myocardial ischemia-reperfusion (I/R) and explore the mechanism.
METHODS: Thirty-six adult SD rats were randomized into sham-operated group, I/R group, AdmiR-NC group and AdmiR-133b group, and rat models of myocardial I/R were established in the latter 3 groups with myocardial injections of saline or recombinant adenoviruses in the left ventricle. The expression of MiR-133b was detected using RT-qPCR, and cardiac function of the rats was determined using FDP 1 HRV and BRS analysis system. Serum CK-MB and cTnI levels were determined by ELISA, myocardial injury was evaluated with HE staining, cardiomocyte apoptosis was detected by flow cytometry, and ROS content was determined using a DCFH-DA probe. In the in vitro experiment, H9C2 myocardial cells with hypoxia/reoxygenation (H/R) treatment were transfected with Mir-NC or MiR-133b mimic, and the cellular expression of MiR-133b, cell apoptosis, and ROS content were determined. Dual luciferase reporter assay was performed to verify the targeting relationship between miR-133b and YES1. The effects of pc-YES1 or miR-133b mimic transfection on YES1 expression, apoptosis, and ROS content in H9C2 cells were evaluated.
RESULTS: Compared with those in I/R group, miR-133b expression was obviously up-regulated, LVEDP, cTnI and CK-MB levels were significantly decreased, and LVSP, +dp/dt, -dp/dt, HR and CF levels were increased in admiR-133b group (P < 0.01). The rats in admiR-133b group showed obviously reduced pathological damage, cell apoptosis and ROS content compared with those in I/ R group (P < 0.01). In H9C2 cells exposed to H/R, transfection with miR-133b mimic significantly up-regulated miR-133b expression and decreased cell apoptosis and ROS content (P < 0.01). The results of dual luciferase reporter assay suggested a direct targeting relationship between miR-133b and YES1, and MiR-133b mimic transfection significantly down-regulated YES1 protein expression in cells with H/R exposure (P < 0.01). Co-transfection with pc-YES1 reversed the effect of miR-133b overexpression on myocardial cell apoptosis and ROS accumulation.
CONCLUSIONS: miR-133b can inhibit I/R-induced myocardial cell apoptosis and ROS accumulation by targeting YES1 to reduce myocardial I/R injury in rats.

Entities:  

Keywords:  YES1; apoptosis; miR-133b; myocardial ischemia-reperfusion; reactive oxygen species

Mesh:

Substances:

Year:  2020        PMID: 33118509      PMCID: PMC7606230          DOI: 10.12122/j.issn.1673-4254.2020.10.03

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  25 in total

1.  MicroRNA-374a protects against myocardial ischemia-reperfusion injury in mice by targeting the MAPK6 pathway.

Authors:  Zhao-Qi Huang; Wei Xu; Jin-Lei Wu; Xiong Lu; Xi-Ming Chen
Journal:  Life Sci       Date:  2019-06-29       Impact factor: 5.037

2.  MicroRNA-133b-5p Is Involved in Cardioprotection of Morphine Preconditioning in Rat Cardiomyocytes by Targeting Fas.

Authors:  Shu-Fang He; Hai-Juan Zhu; Zheng-Yi Han; Hao Wu; Shi-Yun Jin; Michael G Irwin; Ye Zhang
Journal:  Can J Cardiol       Date:  2015-10-30       Impact factor: 5.223

3.  Effect of miR-26a targeting GSK-3β/β-catenin signaling pathway on myocardial apoptosis in rats with myocardial ischemia-reperfusion.

Authors:  D-D Gong; J Yu; J-C Yu; X-D Jiang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-08       Impact factor: 3.507

Review 4.  ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection.

Authors:  Susana Cadenas
Journal:  Free Radic Biol Med       Date:  2018-01-31       Impact factor: 7.376

5.  Delayed coronary reperfusion is ineffective at impeding the dynamic increase in cardiac efferent sympathetic nerve activity following myocardial ischemia.

Authors:  Timothy M Hall; Christina Gordon; Ranjan Roy; Daryl O Schwenke
Journal:  Basic Res Cardiol       Date:  2016-04-19       Impact factor: 17.165

6.  Attenuation of Na/K-ATPase/Src/ROS amplification signal pathway with pNaktide ameliorates myocardial ischemia-reperfusion injury.

Authors:  Hua Li; Anwen Yin; Zijie Cheng; Mengwen Feng; Hao Zhang; Jia Xu; Fei Wang; Lingmei Qian
Journal:  Int J Biol Macromol       Date:  2018-07-03       Impact factor: 6.953

7.  MiR-129-5p protects against myocardial ischemia-reperfusion injury via targeting HMGB1.

Authors:  Z-X Chen; D He; Q-W Mo; L-P Xie; J-R Liang; L Liu; W-J Fu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-04       Impact factor: 3.507

8.  MicroRNAs associated with ischemia-reperfusion injury and cardioprotection by ischemic pre- and postconditioning: protectomiRs.

Authors:  Zoltán V Varga; Agnes Zvara; Nóra Faragó; Gabriella F Kocsis; Márton Pipicz; Renáta Gáspár; Péter Bencsik; Anikó Görbe; Csaba Csonka; László G Puskás; Thomas Thum; Tamás Csont; Péter Ferdinandy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-23       Impact factor: 4.733

9.  Rosmarinic acid alleviates cardiomyocyte apoptosis via cardiac fibroblast in doxorubicin-induced cardiotoxicity.

Authors:  Xin Zhang; Jin-Xiu Zhu; Zhen-Guo Ma; Hai-Ming Wu; Si-Chi Xu; Peng Song; Chun-Yan Kong; Yu-Pei Yuan; Wei Deng; Qi-Zhu Tang
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

10.  MiR-484 Protects Rat Myocardial Cells from Ischemia-Reperfusion Injury by Inhibiting Caspase-3 and Caspase-9 during Apoptosis.

Authors:  Huizi Liu; Sai Li; Wei Jiang; Yinjun Li
Journal:  Korean Circ J       Date:  2019-11-19       Impact factor: 3.243

View more
  1 in total

1.  CBL knockdown protects cardiomyocytes against hypoxia-reoxygenation injury by downregulating GRB2 expression.

Authors:  Zhengbing Lv; Xiaojia Luo; Biying Hong; Qiran Ye; Jianxiong Liu; Yongmei Hu
Journal:  Exp Ther Med       Date:  2022-01-03       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.